Endocrine and Reproductive Peptide Medicines

What this page covers

Some of the oldest peptide medicines copy or block pituitary and hypothalamic hormones. This page covers four examples: desmopressin (a vasopressin analogue, brand DDAVP), oxytocin (Pitocin), leuprolide (a GnRH agonist, brand Lupron Depot) and octreotide (a somatostatin analogue, brand Sandostatin). Each acts on a different hormone system and has its own approved uses and risks. They are not interchangeable and none is a general "hormone booster". The page gives no amounts, no injection instructions and no advice to start, stop or switch a medicine.

Evidence labels: approved medicine means the named regulator has approved the product for the stated use. All label statements come from US FDA labels on DailyMed, read 2026-10-22; the DDAVP tablet and Pitocin labels use an older format. Other countries were not checked. Labels change.

Summary table

Desmopressin

How it works. Desmopressin acts on vasopressin V2 receptors in the kidney to increase water re-absorption and reduce urine production. It has a longer duration and less pressor effect than natural vasopressin. [2]

Uses. The DDAVP tablet label lists central (cranial) diabetes insipidus, including temporary excess urination after pituitary surgery or head injury, and primary nocturnal enuresis, which it says may be used alone or alongside behavioral conditioning. [1] It is not effective for nephrogenic diabetes insipidus. [2] The injection label adds hemophilia A and mild-to-moderate type I von Willebrand's disease. [2]

Safety. The injection label carries a boxed warning for hyponatremia (low blood sodium), which can lead to seizures, coma, respiratory arrest or death; it is contraindicated in people at higher risk, such as those with excessive fluid intake, those on loop diuretics or systemic or inhaled glucocorticoids, and those with moderate to severe kidney impairment. [2] The label calls for normal serum sodium before starting and for sodium checks after starting and periodically. [2] The older tablet label warns of water intoxication and hyponatremia, especially in children and older adults, and says fluid intake should be adjusted. [1]

Oxytocin

Oxytocin is a hormone that causes the uterus to contract. [3] The Pitocin label gives approved uses (medically indicated induction of labor, stimulation of weak labor, help with incomplete or inevitable abortion, and control of bleeding after delivery) and says it is not indicated for elective induction of labor. [3] For labor it is given only by intravenous infusion with adequate medical supervision in a hospital, with continuous observation. [3] Reported maternal adverse reactions include postpartum hemorrhage, cardiac arrhythmia, hypertensive episodes and uterine rupture; excessive dosage or hypersensitivity can cause uterine hypertonicity, spasm or rupture. [3] This is a hospital obstetric medicine. Oxytocin products marketed for other purposes are not covered by this label; see oxytocin.

Leuprolide (GnRH agonist)

Leuprolide is a GnRH agonist. After an initial rise, continuous exposure suppresses gonadotropin release and then ovarian and testicular hormone production, according to animal studies cited in the label; the effect was reversible after stopping. [4] The main US Lupron Depot label read covers advanced prostate cancer. [4] Separate Lupron Depot labels cover endometriosis (alone or with norethindrone add-back therapy) and, with iron, the preoperative treatment of anemia caused by fibroids. [5]

Safety items from the labels:

• Tumor flare. Testosterone rises about 50% above baseline in the first weeks, and symptoms such as bone pain can worsen early in prostate cancer treatment. [4]


• Metabolic and heart. Hyperglycemia, diabetes and lipid changes may occur, and heart attack, sudden cardiac death and stroke have been reported with GnRH agonists in men, with the risk described as low. [4]


• Women's labels. Loss of bone density (some may not be reversible), harm to a fetus (contraindicated in pregnancy), and severe skin reactions. [5]

Agonists and antagonists differ; see GnRH agonists and antagonists.

Octreotide

The Sandostatin label says octreotide mimics natural somatostatin and is an even more potent inhibitor of growth hormone, glucagon and insulin; by these effects it is used for symptoms of carcinoid tumors and VIPomas. [6] In acromegaly it is approved to lower growth hormone and IGF-1 in people who did not respond adequately to surgery, irradiation and bromocriptine or cannot be treated with them. [6] The label notes that improvement in signs and symptoms, or tumor size or growth, was not shown in the trials, which were not designed to detect such effects. [6] Warnings include heart conduction problems such as atrioventricular block, gallbladder abnormalities, and either high or low blood sugar. [6] Lowering growth hormone or IGF-1 is a disease-specific laboratory goal in acromegaly, a rare condition; it says nothing about growth-hormone-related peptides sold for other purposes. See somatostatin analogues.

Professional-care context

These are specialist-prescribed medicines used for diagnosed endocrine, reproductive, cancer or obstetric conditions, with laboratory and clinical monitoring that the labels describe. For general background see thyroid and fatigue, and for medicines in pregnancy see pregnancy and breastfeeding. Research on peptides for sexual and reproductive health beyond these labels is covered in peptides: sexual and reproductive health. Individual guides: desmopressin.